Skip to content
by Legal Desire
5 December 2024

Latham & Watkins Advises Revolution Medicines in Upsized US$750 Million Public Offering of Common Stock and Pre-Funded Warrants

Advising firms

Deal team

17 lawyers named
LawyerFirmSeniorityPracticeOffice
Mark Roeder Lead Latham & Watkins LLP Partner corporate Bay Area
John Williams Lead Latham & Watkins LLP Partner corporate Bay Area
Zuza Gruca Latham & Watkins LLP Associate corporate Not stated
Lexi Zintel Latham & Watkins LLP Associate corporate Not stated
John Manthei Latham & Watkins LLP Partner regulatory Washington, D.C.
Elizabeth Richards Latham & Watkins LLP Partner regulatory Washington, D.C.
Heather Deixler Latham & Watkins LLP Partner regulatory Bay Area
Betty Pang Latham & Watkins LLP Partner regulatory Bay Area
Nathan Beaton Latham & Watkins LLP Associate regulatory Not stated
Leia Gu Latham & Watkins LLP Associate regulatory Not stated
Evan Miller Latham & Watkins LLP Associate regulatory Not stated
Grace Lee Latham & Watkins LLP Partner tax Bay Area
Derek Gumm Latham & Watkins LLP Associate tax Not stated
Rasha Suleiman Latham & Watkins LLP Associate tax Not stated
Christopher Hazuka Latham & Watkins LLP Partner intellectual property San Diego
Robert Yeh Latham & Watkins LLP Associate intellectual property Not stated
Patrick Chew Latham & Watkins LLP Associate intellectual property Not stated

Stated terms

Stated value
USD 750m (US$750 million)
What the figure measures
Issue size
Client
Revolution Medicines, Inc.Issuer
Counterparties
Not stated